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Abstract A novel poinL mutation in the 3-liydroxy-3-methyl“ 
glutaiy 1 coenzyme A lyase gene was found in a Turkish patient 
with homozygous 3-hy droxy-3-methylglu.taric acidemia. Am­
plification by RT-PCR of the mRNA using six different pairs 
of oligonucleotides produced 110 differences in four of the 
fragments amplified with respect to the control, but gener­
ated two fragments of different size. One was representative 
of a deletion of 126 bp and the other of an insertion of 78 
bp. These abnormal mRNAs resulted from a G —> C transver­
sion at the nucleotide +1 of an intron, which changed the 
invariant GT dinucleotide of the 5' donor splice site. This was 
associated with the occurrence of an alternative splicing, 
which led to the skipping of the whole exon of 126 bp, and 
also with the activation of one cryptic donor splice site in the 
same intron. These aberrant splicccl mRNAs are predicted to 
encode two abnormal HMG-CoA lyase proteins: the first re­
sults in a protein with an internal deletion of 42 amino acids, 
whose enzyme activity is largely abolished, as the catalytic site 
was completely removed; the second contains 17 missense 
amino acids that precede a stop codon. Northern blot analysis 
showed that the overall content of these aberrantly spliced 
mRNAs in pro band fibroblasts was the same as that found in 
control fibroblasts. However, hardly any transcript was ob­
served corresponding to the inserted mutated mRNA when 
it was examined by a specific probe. To quantify the relative 
proportion of the two mRNAs, a quantitative RT-PCR (the 
DNA-mimic PCR reaction) was carried out. Results show that 
the proportion of the inserted mRNA with respect to the de­
leted mRNA is only 1.2%. The father, mother, and two broth­
ers of the proband were heterozygous in the G —> C mutation 
in the +1 nucleotide of the intron considered, while the two 
alleles of another brother were free of the mutation.—Buesa, 
C., J. Pié, A, Barceló, N. Casals, C. Mascaró, C. H. Casale, D. 
Haro, M. Duran, J. A. M. Smeitink, and F. G. Hegardt. Aber­
rantly spliced mRNAs of the 3-hydroxy-3-methylglutaryl coen­
zyme A lyase (HL) gene with a donor splice-site point muta­
tion produce hereditary HL deficiency .J. Lipid Res. 1996. 37:
2420-2432.
Supplementary key words HMG-CoA lyase deficiency * ketone bod­
ies • leucine metabolism • donor splice site • exon skipping
3-Hy droxy-3-m e thylglutaryl c o e n zym e A (HMG-CoA) 
lyase (HL)(1), (EC 4.1.3.4) is a mitochondrial enzyme 
that catalyzes the cleavage of HMG-CoA to acetyl-CoA 
and ace to ace tic acid. This reaction is the common final 
step of the Ice to genic pathway and the catabolic pathway 
of leucine (Fig. 1). The functional avian enzyme is a 
dimer of 31.4 kDa located in the mitochondrial matrix 
(2, 3) and the size of human HL is 31.6 kDa (3). Ketone 
bodies (acetoacetate and D-3-hydroxybutyrate), as oxi­
dative fuels, can act as alternative substrates to glucose 
for peripheral tissues, but they also have pivotal roles 
as lipogenic precursors and as regulators of metabo­
lism (1).
In humans, the deficiency of HMG-CoA lyase is a rare, 
clinically heterogeneous inborn error of metabolism, 
with a bimodal distribution, with about 30% of cases 
appearing between 2 and 5 days of life^  60% between 3 
and 11 months. This disease usually presents with vom­
iting, hypotonia, and lethargy, which progresses to
Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl coenzymc A; 
HL, HMG-CoA lyase gene; RT-PCR, reverse transcription-polymerase 
chain reaction.
'Present address: Unit of Human Physiology, College of Huesca, 
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Fig. l. Metabolic interrelationships of 3-hydroxy-3-methylglutaryl~CoA (HMG-CoA). The site of the defect in patients with HMG-CoA lyase 
deficiency is indicated by the cross-hatched box. In liver, HMG-CoA lyase, along with mitochondrial HMG-CoA synthase, plays a critical role 
in the production of ketone bodies. In other tissues Jackingmitochondrial HMG-CoA synthase, HMG-CoA lyase is primarily involved in leucine 
degradation.
coma in about 10% of cases. All patients have metabolic French-Canadian siblings (3) with the disease has 
acidosis and they are prone to severe hypoketotic hypo- shown the occurrence of a small deletion of two nucleo-
glycemia on fasting, hyperammonemia, hepatomegaly, tides determining a truncated protein in the amino ter-
and elevation of transaminases. Some patients were minal domain, thus unable to perform catalytic ITMG-
macrocephalic and severely mentally retarded, one was CoA lyase activity. More recently, a new frameshift 
microcephalic, and many presented developmental de- mutation has been diagnosed, produced by the inser-
lay (4, 5). This autosomal recessive disease has proven 
fatal in about 20% of cases (6-9) and, in other cases, 
fatal cardiomyopathy (10) and sudden infant death syn­
drome (11) have been associated with HL deficiency. A 
number of patients have either been initially diagnosed 
with Reye’s syndrome or described as having symptoms 
veiy similar to those of Reye’s syndrome (12-14).
The characteristic abnormal metabolites in urine in-
tion of one nucleotide (16) determining an HL activity 
of the encoded protein of less than 7% of control 
values.
We report here the diircl genetic study performed, in 
a patient of Turkish origin with a biochemically con­
firmed diagnosis of deficiency of HMG-CoA lyase. The 
donor splice site mutation in the HL gene, leads to two 
aberrantly spliced mRNAs, one producing the skipping
elude 3-hydroxy-3-methylglutaric acid and others de- of an exon of 126 bp and the other producing an inser- 
rived from the metabolism of leucine (Fig. 1). The tion of 78 bp originally present in the downstream in­
amount of residual enzymatic 3~hydroxy-3-methylglu- tron. The proteins encoded by these abnormal mRNAs 
taryl-GoA lyase activity was shown to be essentially the would be unable to act as efficient enzymes as i) the 
same in fibroblasts of the patients with a mean of 1.1% truncated protein corresponding to the deletion af-
of the normal range (15).
Recently, cDNA clones for 3-hydroxy-3-methylglu- 
taryl-CoA lyase were obtained from both chicken and 
human cDNA libraries (3) and the gene was assigned to 
the distal short arm of human chromosome 1. Human
fee ted most of the catalytic site, and it) the protein cor­
responding to the insertion contains 17 aberrant amino 
acid residues preceding a stop codon, and lacks the im­
portant Cys-323 necessary to conform the physiological 
homodimeric enzyme. Further, the expression of the
fibroblasts and liver show a single 1.7-kb mRNA on mRNA with the insertion is largely abolished. This was 
Northern blots. The genetic study in two Acadian observed not only by Northern blot, but also by a quanti-
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tative RT-PCR (the DNA-mimic PCR reaction), which 
showed that the amount of mRNA with the insertion 
was only 1.2% of that of the mRNA with the deletion.
MATERIAL AND METHODS
Subjects
The proband (E.G.) was a 4-day-old male born to 
Turkish parents, who on physical examination had all 
the clinical features (i.e., tachypnea, hepatomegaly, 
lethargy, and hypotonia) of classical HMG-CoA lyase de­
ficiency. The organic acids found in blood atid urine 
confirmed this diagnosis. He was treated at the Williel- 
mina Kinderziekenhuis at Utrecht (Netherlands) with 
intravenous glucose and NaHCOs solutions, and he re­
covered within a few days. The proband’s parents and 
brothers were asymptomatic, with serum glucose con­
centrations in the normal range. All subjects gave their 
informed consent for this study.
Biochemical analysis
All common biochemical analyses, such as blood glu­
cose, ketone bodies, transatninases, and organic acids 
in blood and urine, were carried out in the laboratory 
of the Willi elmina Children’s Hospital at Utrecht.
Fibroblast culture
A skin biopsy was taken from the proband and every 
member of his family. Explants were cultured in 25-cm2 
flasks in minimal essential medium (MEM), 100 IU / 
ml of penicillin, and 50 mg/ml of streptomycin, 2 mM 
glutamine, 10% fetal calf serum, and 95% air-5 % C02,
Southern blot analysis
Genomic DNA was extracted from cultured fibro­
blasts by a standard procedure (17). DNA was digested 
using 5-10 U/mg of several restriction enzymes, sepa­
rated by agarose gel electrophoresis, transferred to ny­
lon membranes, and hybridized with human TIL cDNA 
probes as reported (3).
RT-PCR conditions
Poly(A+)-rich RNA was purified and a first strand 
cDNA was synthesized at 37°C for 1 h with the ready to 
go T-primed First-Strand kit of Pharmacia Biotech. The 
oligonucleotides used in the PCR-RACE experiments 
were synthesized by Pharmacia. Radioactive compounds 
were obtained from Amersham. The primers used in 
the amplifications were:
orf-f 5' GGCCAAGATGGCAGCAATG 3' (bases -7 to 12 
from human cDNA) (15);
orf-r 5' CCCTATTTCCACATCATCCC 3' (bases 1022 to 
1002 from human cDNA);
f l 5' ATAGACATGCTTTCTGAAGC 3' (bases 177 to 
197 from cDNA);
f2 5' CTGCCTCAGAGCTCTTCACC 3' (bases 386 to 
405 from cDNA);
f3 5' AGATCTCCCTGGGGGACACC 3' (bases 596 to 
615 from cDNA);
f4 5' CTTGGAGGCTGTCCCTACGC 3' (bases 787 to 
806 from cDNA);
iT 5' CTTAGGAGACACAAAGCTGG 3' (bases 240 to 
221 from cDNA);
r2 5' CTGAAAACTCTCCTCTATGG 3/ (bases 444 to 
425 from cDNA);
r3 5' ATGTCTTTCATGATCCCTGG 3' (bases 650 to 
631 from cDNA);
r4 5' TGGCCAAGTTTCCTGATGCC 3' (bases 832 to 
813 from cDNA);
f3bis 5' AGACCTTGATGGCCCTGCA 3' (bases 731 to 
74-9 from cDNA);
r4bis 5' CATCGACTTTTGTTCTCAGC 3' (bases 75 to 
56 from the inserted sequence from the intron).
The PCR amplification conditions were as follows: 1 
min at 94° C, 30 sec at 55° C, 30 sec at 72°C, then 35 
cycles and a final extensions of 20 min at 72°C. Taq 
DNA Polymerase was purchased from Perkin-Elmer. 
PCR products were separated from each other and from 
the unincorporated primers by electrophoresis on a 2% 
agai~ose gel. After staining with ethidium bromide, the 
bands were excised and DNA was extracted from the 
gel using Quiaex (Diagen, GmbH, Germany).
DNA sequencing
Purified PCR amplification products were sequenced 
either by the dicleoxynucleotide chain termination 
method (18) with modified T7 DNA polymerase 
(Sequenase, United States Biochemical), or automati­
cally with an Applied Biosystems 373 DNA sequencer 
using the fluorescent terminator kit (Perkin-Elmer).
PCR amplification of genomic DNA
To amplify the region of HL encompassing the point 
mutation at the 5' end of the intron, 1 |Xg of genomic 
DNA was amplified in a 100 (il mixture containing 0.2 
mM of each dNTP, 50 pmol of each primer, 2.5 units 
of Taq DNA polymerase in 1 X PCR buffer and 1.5-5 
mM MgClo. f4 forward primer (see above) and orf-r re­
verse primer were used. The conditions were: 98°C for 
10 min, 55°C for 30 sec, 72°C for 1.5 min for the first 
time and subsequently 94°C for 1 min, 55°C for 30 sec, 
72°C for 1.5 min for 30 cycles. PCR products were sepa­
rated and purified (see above).
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RNA blot analysis
Total RNA from the cultured fibroblast was isolated 
as described (19). RNA samples were fractionated in 1 % 
agarose/formaldehyde gels, transferred to Nytran-N 
membranes (Schleicher & Schuell) and cross-linked by 
heat. Hybridizations were carried out as described (17) 
using either the full-length HL cDNA or the mentioned 
parts of it as a probe (RT-PCR conditions), and washes 
were performed at 68°C in 0.2X SSG (IX  SSC is 0.15 
m NaCl, 0.015 m Na citrate, pH 7.0), and 0.1% sodium 
doclecyl sulfate. mRNA levels were measured by densi­
tometry of the autoradiograms with a Molecular Dy­
namics computing densitometer. Densitometry values 
were corrected using human p-actin as a constitutive 
probe. Filters were dehybridized either in water at 
100°C for 10 min or in 50% formamide/6X SSPE at 
70°C for 2 h (IX  SSPE is 0.15 M NaCl, 10 him sodium 
phosphate, pH 7.4-, 5 mM Na2EDTA).
Transcriptional analysis of the levels of the two 
mRNAs for HMG-CoA lyase by amplification 
of a competitive PCR
Generation of the competitive PCR fragment (DNA-mimic). 
DNA-mimic is a cDNA fragment used as competitive in­
ternal standard in PCR amplification, which may be 
used for quantitation of mRNA levels of target genes. 
Two DNA-mimics were prepared. The first to measure 
the proportion of the mRNA with the insertion, and the 
second to determine the amount of the two mRNAs, 
Both DNA-mimics were constructed by two rounds of 
PCR amplification of the generic DNA fragment EcoJtl- 
BcmMl (0.6 kb) of the v-erb B oncogene (20), using spe­
cific primers: the forward primer f3 was the same in the 
determination of both DNA-mimics. The reverse prim­
ers were different in each case. To quantify the mRNA 
with the insertion, the primer r4 was chosen in the exon 
preceding the insertion, so the deleted mRNA could 
not be amplified. To quantify the mixture of both 
mRNAs the primer (orf-r) of the next exon was chosen,
In the first PCR reaction in each case, two composite 
primers were used. Each composite primer had the mi­
tochondrial HMG-CoA lyase gene primer sequence 
attached to a short, 20-nucleotide stretch of sequence 
designed to hybridize to opposite strands of a heterolo­
gous DNA fragment (0.6 kb EcoRI-BamHI of the v-erb 
B oncogene). This ensured that all DNA-DNA-mimic 
molecules had the complete gene-specific primer se­
quences. These composite primers have the following 
sequences:
foward primer: 5' AGATCTCCCTGGGGGACACCCG 
CAAGTGAAATCTCCTC 3';
reverse primer-1: 5' TGGCCAAGTTTCCTGATGCCTT 
GAGTCCATGGGGAGCT 3';
reverse primer-2: 5' CCCTATTTCCACATCATCCCTT 
GAGTCCATGGGGAGCT 3'.
The procedures for primary (a) and secondary ampli­
fication (b) are the following, a) The primary amplifi­
cation was carried out in a final volume of 50 \il with 5 
pi of PGR buffer, 0.2 mM dNTP each, 2 ng of v-erb B 
DNA fragment, 0.4 \x m  each composite primer, and 
2.5U Taq DNA polymerase. The cycle parameters were: 
denature 45 sec, 94°C, anneal 45 sec, 60°C, and extend 
90 sec, 72°C, 16 cycles. A dilution of the first PCR reac­
tion was then amplified again using only the gene-spe­
cific primers.
b) Two ill of the primaiy PCR reaction was removed 
and diluted in 200 (ill in water. Two \i\ of this dilution 
was used to cany out the secondary amplification, un­
der the same conditions as the first, but using the spe­
cific primers depending on the mRNA to be analyzed. 
In the case of the mRNA with the insertion, the foward 
primer was taken from the previous exon of HMG-CoA 
lyase, 5' AGATCTCCCTGGGGGACACC 3' and from 
the deleted exon of HMG-CoA lyase (reverse) 5' 
TGGCCAAGTTTCCTGATGCC 3' to a total of 25 cycles. 
In the case of the quantification of both mRNAs the 
forward primer was the same and the reverse primer 
was taken from the exon that follows the deleted exon:
5' CGCTATTTCCACATCATCCC 3'. After the second 
PCR amplification the PCR DNA-mimics were purified 
by passage through CHROMA SPIN+TE-100 columns 
(Ciontech Laboratories). The yield of the DNA-mimics 
was then calculated by absorbance at 260 nm.
Analysis of the levels of the deleted ancl inserted mRNAs. 
Poly A-f-rich RNA was purified and a first strand cDNA 
was synthesized with the reverse transcriptase (RT). The 
‘reaction was set up in 20 |-il of a mixture containing 0.1 
\ig of DNA-free mRNA (in water), 0.4 |Llg of utr-r primer 
5' CGTAGCTCTCCACTTTCCAC 3' (bases 1485 to 1505 
from human ITL cDNA), 10 mM dithiothreitol, 0.5 mu 
deoxynucleoside triphosphates, 4 |al of 5X RT buffer 
(250 mM Tris/HCl, pH 8.3; 375 mM KC1, and 15 mM 
MgCl2) and 200 U of mouse mammaiy leukemia vi­
rus reverse transcriptase (Bethescla Research Labora­
tories), and incubated at 37°C for 60 min, heated to 
95°C for 5 min, and then quick-chilled in ice. The cDNA 
was amplified using the orf-f and utr-r primers. The am­
plification conditions were as follows: 1 min at 94°C, 30 
sec at 55°C, 90 sec at 72°C, then 35 cycles and a final 
extension of 20 min at 72°C. The final product was used 
as a template to amplify the fragments used in the com­
petitive PCR.
The HMG-CoA lyase mRNA levels were determined 
by PCR co-amplification as follows. Three \±\ of the am­
plified cDNA fragment (orf-f--utr-r) and increasing 
amounts, between 6 and 3.75 X 103 attomoles, of DNA 
mimic were added to the reaction mixture composed
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of 4 \i\ of PCR buffer (100 mM Tris-HCl, pH 8.3, 50 mM 
KC1, 1.5 mM MgCl2), 0.2 mM dNTP each, 0.2 |lim each
composite primer, and 2 U ampliTaq DNA polymerase
(5 U/id) and 2.5 |LiGi (0.25 |u.1) of [a-32P]dCTP (3,000
Ci/mmol; Amersham) to a final volume of 50 jul. As 
the estimated amounts of the mRNA with deletion were 
much higher than the mRNA with the insertion, the 
determination was carried out in the same manner but 
diluting (1/10) the amplified cDNA (orf-f-utr-r) used 
before, and increasing amounts, between 3.6 X 102 and
22.5 X 101 attomoles, of the DNA mimic. PCR was per­
formed for 25 cycles. The amplification was carried out 
using the following cycle parameters: denature 60 sec, 
94DC, anneal 75 sec, 59°C, and extend 45 sec, 72°C. The 
primers were from the previous exon of HMG-CoA lyase
(forward), 5' AGATCTCCCTGGGGGACACC 3' and
from the next exons of HMG-CoA lyase (reverse) 5'
TGGCCAAGTTTCCTGATGCC 3' and 5' CCCTATTTC 
CACATCATCCC 3'. The reaction products (10 jol) were 
analyzed on 1.8% agarose gels in Tris acetate/EDTA 
(10 itim/1 mM) buffer pH = 8, visualized by staining 
with ethidium bromide, and documented on Polaroid 
no. 665 film. For quantitation of relative band intensi­
ties, gels were cut and counted in a liquid scintillation 
counter.
RESULTS
Clinical data
Routine clinical chemical analysis of the proband 
(E.C.) revealed the following data: glucose l mM (N
2.8-6.0), ALT 291 U /I (N 7-43), AST 495 U /I (N 3- 
47), uric acid 1.14 mM (N 0.05-0.40), pH 7.07, pC02
3.8 kPa, standard bicarbonate 7.9 mmol/1 (N 21-28). 
Cerebrospinal glucose was 1.2 mM (N 3.2-4.5). Selec­
tive screening for inborn errors of metabolism showed 
3-hydroxyisovaleric, 3-methylglutaric, 3-methylglu la­
conic, and 3-hydroxy-3-methylglutaric acids to be very 
high in urine. Neither acetoacetic nor (3-hydroxybutyric 
acid was found. A confirmatory enzyme diagnosis was 
made in isolated platelets, with an HL activity of <0.1 
nmol/protein per min. (N: 27.5 ± 3.9). The activities 
found in the parents and two brothers were in the het­
erozygous range. Another brother had normal activity.
Southern blot analysis
To rule out the presence of major structural defects 
of HMG-CoA lyase gene, genomic DNA from the pro­
band, from his relatives and from a normal control sub­
ject was digested with EcoRl and H indlll. After Southern 
blotting and hybridization with the HL cDNA as a
probe, no major rearrangements of the HL gene were 
detected (data not shown).
Reverse transcription PCR (RT-PCR)
Fibroblast cultures obtained from skin biopsies on 
E.C. were used for the extraction of RNA, which was 
then used as a substrate for the first strand cDNA syn­
thesis. This cDNA was used as a template for the ampli­
fication by PCR of different overlapping fragments, as 
summarized in Fig. 2A. Figure 2B shows the amplified 
fragments obtained from control human placenta 
mRNA and also the fragments amplified from the pa­
tient cDNA. The size of the fragments amplified from 
the patient was different from the control in some cases. 
First, the amplified fragment orf-f/orf-r from the pa­
tient was about 900 bp in comparison with the 1024 bp 
found in control with this set of primers; second, frag­
ment 15 obtained with primers f4 and orf-r showed a 
clearly altered electrophoretic mobility (310 bp in the 
patient in contrast to 236 bp in the control); and third, 
amplification 16 obtained with primers f3 and orf-r also 
showed a significant difference in size between the pa­
tient and control (about 300 bp in the patient instead of 
429 bp obtained from human placenta control mRNA). 
These findings thus indicated that two HL mRNA spe­
cies were present in proband fibroblasts.
Sequence of the RT-PCR fragments
PGR fragments 15 and 16 from the patient were puri­
fied and sequenced. Fragment 16 revealed a 126 bp de­
letion from nucleotide 751 to 876 in the human lyase 
cDNA. In contrast, fragment 15 revealed a 78 bp inser­
tion starting at the nucleotide 876 (Fig. 3A). We had 
thus found a deletion in one mRNA and an insertion 
in the other mRNA, located close to the left and to the 
right of the same nucleotide, respectively. After both 
the insertion and the deletion, the nucleotide sequence 
was identical to the cDNA from normal (control) hu­
man HMG-CoA lyase.
PCR amplification and sequence of the exon deleted 
and the downstream boundary intron
To explore the origin of the insertion and deletion,
_ i
we performed PCR amplifications to establish the ge­
nomic organization of the HL gene at the bounda­
ries of nucleotides 751 and 876 respectively. Using f4 
and orf-r as primers, a fragment of about 2.1 kb was 
amplified by PCR using genomic DNA as a template. 
This amplification always yielded the same fragment 
whether control or patient genomic DNA was used. 
After purification, this fragment was sequenced using 
the oligonucleotide f4 as a primer. Nucleotide 876 was 
identified as the 3' boundary of an exon. Control geno­
mic DNA revealed a canonical splicing donor sequence
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5'UTR
1
orf-f
orf-f
ORF: 1024 bp
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3'UTR
i ,
orf-r
orf-r
14; 237 bp
15: 236 bp
16:429 bp
CONTROL
mk 15 14 13 12 11 mk
PATIENT
mk 15 14 13 12 II orf mk 16ct mk 16pt
Fig. 2. Top: The pattern of PCR amplifications using different sets of specific oligonucleotides is shown. Bottom: The different amplified 
fragments of the control and of the patient were separated by electrophoresis in 1 % agarose.
(glaag) following nucleotide 876. This sequence re- occurs at the authentic splice sites and leads to the skip-
vealed a G —> C transversion in the patient DNA, which ping of the exon mentioned, 
gave the non-donor-splicing consensus claag. Thus the
78 bp inserted in the mRNA was the 5' region of the PCR amplifications of the relatives of the proband
downstream flanking intron. A cryptic splicing donor mRNAs were also isolated from cultured fibroblasts 
sequence (gtall) was found in nucleotides 79-83 of this of the father, the mother, and three brothers of the pro- 
intron (Fig. 4), suggesting that this cryptic donor se- band. After conversion to the corresponding cDNAs, 
quence was used by the spliceosome to produce a ma- they were amplified by PCR (RT-PCR) using the prim- 
ture mRNA with the 78 bp sequence added to the previ- ers f3 and orf-r to detect the deletion. Two amplification
bands corresponding to the nonmutated and mutated 
mRNAs are seen in the father, the mother, and two of
ous exon.
Figure 4 summarizes the results of the nucleotide se­
quences obtained. The G C transversion, which con- the brothers (GC and UC) (Fig. 5A). The bigger band 
verts the invariant gt of the donor splice site into ct9 sug- corresponds to the nonmutated mRNA and the smaller 
gested that the disruption of the normal splicing of ITL to the mutated mRNA (in this case the mRNA is the 
mRNA in proband E.C. was due to the elimination of one deleted). However, only one band is seen in the 
the 5' donor splice site of the intron. Figure 4 also shows third brother (ICC), suggesting that this boy has not in­
itial the presence of a cryptic donor splice site in the herited the mutated allele, and is not a carrier of the 
intron (at nucleotides 79-83) allows an alternative ab~ disease. The rest of the family are carriers (Fig. 5B). 
normal splicing to occur. This leads to the incorpora- The consanguinity of the couple was confirmed by this 
tion of 78 bp of intron at the 3/ boundary of the exon. experiment.
The second mRNA species found in the proband de- In addition, we performed PCR amplifications using
rives from the activation of an alternative splicing that the genomic DNA as a template in both parents. With
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A
Deleted mRNA
750 877
GGCCCTGCAG
126 bp d e l e t e d
GGTG TGAATCTCCA
Inserted mRNA
87 6
CACACG CTAAGCCCAC CCACCCCCTG
877
ACCAGGGGGC CTGAAGCTGA GAACAAAAGT GGATGGGG GGTG TGAATCTCCA
Fig. 3. A: The sequence of the boundaries of the de­
leted 126 bp in the bp mRNA, ancl the intronic se­
quence of 78 bp corresponding to die insertion in the 
mRNA (underlined), are shown. The figures corre­
spond to the coordinates of nucleotides of the cDNA 
of human HMG-CoA lyase (15). The TGA stop codon 
from the intron sequence is located at position 78. B: 
The sequence of amino acid residues corresponding 
to the control HMG-CoA lyase, and that of the two 
mutated mRNAs are shown. The 17 amino acid resi­
dues inserted, which precede a stop codon, are shown 
in black. The catalytic Cys-266 is marked with an as­
terisk.
HMG-CoA Lvase wild type
250 270 
i
290 310
ALTNTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL
*
HMG-CoA Lvase inserted
ALTNTLMALQMGVSWDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTLSPPTPWWRQPRTDQGA
*
HMG-CoA Lvase deleted
ALTNTLMALQ GVNLQKLLEAGNFICQALNRKTSSKVAQATCKL
the same primers as those used in the proband, an iden- among them the Cys-323, which is responsible for the
tical 2.1 kb fragment was amplified. The fragment was formation of the homodimer protein found in eukary-
sequenced using the oligonucleotide f4 as a primer. We otes (21, 23). Neither predicted proteins would be cata-
found that in the position of the nucleotide +1 of the lyrically active, producing the observed absence of enzy-
intron there was a mixture of c (corresponding to the matic activity in fibroblasts in the homozygous proband,
mutated allele, like the proband) and g (corresponding 
to the wild-type allele). This result indicated that both 
parents were carriers of the same point mutation, cor­
roborating their consanguinity.
Predicted translation products of HL mRNAs
Quantification of the inserted and deleted 
mRNA levels
As the amplification of the cDNA using the primers 
orf-f and orf-r and the cDNA obtained from the mRNA 
from the patient as a template yielded only one 900-bp
The 126~bp in-frame deletion produces die loss of 42 fragment instead of the two fragments expected (900
amino acids (Met-251 to Thr-292) in the mature pro­
tein. This deleted region includes the important Cys-
bp of the deleted mRNA and 1100 bp of the other 
mRNA), we determined the levels of each mutated 
266 of the catalytic site (21, 22). The 78-bp insertion mRNA, (that with deletion and that with the insertion) 
does not affect the catalytic cysteine but produces mis- by Northern blot. As a first probe, fragment 11 of 247 
sense codons starting at Thr-292, which leads to a stop bp, which was amplified from orf-f and rl, was used, 
codon 18 triplets downstream (Fig. 3B). In this case, the This probe recognized the two overlapping mRNAs. 
mature protein has 17 missense amino acids that follow Then a specific probe was used to determine whether 
Thr-292, and lacks the last 16 sense amino acid residues, the mRNA with the insertion was produced. This probe
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Exon X -l ExonX Exon X+l
a) Normal
CG/gtaag^,
/  \
mRNA
DNA
b) Deletion 
of 126 bp
CG/ctaag^ ,^
mRNA
DNA
c) Insertion 
of 78 bp DNA
mRNA
Fig. 4, Schematic representation of the abnormal splicing of HMG-CoA lyase mRNA in proband E.C, The G 
—» C transversion (marked with an asterisk (*)) eliminates the 5' donor splice site in die intron and allows 
the formation of another mRNA species as a result of the skipping of the whole exon; in addition, the activation 
of one cryptic donor splice site in the same intron determines the formation of another abnormal mRNA.
was amplified by using two specific primers: f3b, which 
is immediately before the 5' flanking region of the de­
leted sequence, and a reverse primer, r4b located in po­
sition 76-56 of the inserted intron sequence. These 
primers amplified a 223-bp fragment from the cDNA 
of the patient, which could specifically recognize the 
inserted mRNA. The mRNA with the deletion could not 
be hybridized with this probe as its first 126 bp are ab­
sent due to the exon skipping, and the last 76 bp are 
also absent because they are a part of the intron se­
quence.
mRNAs from the patient and the healthy unrelated 
control were thus analyzed in Northern blot experi­
ments. The membrane was then divided into two halves 
and processed. In one half a similar expression was ob­
served in the proband and in the control when hybrid­
ized with the probe of 247 bp corresponding to ampli­
fication 11. In the other half of the membrane, hardly 
any expression of the inserted mRNA was detected in 
the proband when it was hybridized with the specific 
probe prepared for the inserted mRNA (see above), 
even when the film was overexposed for more than 3 
weeks (Fig. 6). These results were interpreted to mean 
that the mRNA with insertion was present in much
lower amounts than the mRNA with deletion, thus 
scarcely contributing to the production of active HMG- 
CoA lyase.
As the Northern blot determinations did not afford 
quantitative evidence of the inserted or deleted mRNA 
levels, we performed quantitative determinations of die 
two mRNAs taking advantage of the quantitative RT- 
PCR determination (the DNA-mimic PCR reaction). To 
this end, we used two DNA-mimic templates as internal 
standards (one for the inserted mRNA, the other for 
the two mRNAs), as the amplification takes place in a 
competitive fashion because the DNA-mimic and mito­
chondrial HMG-CoA lyase sequences compete for the 
same primers,
We first prepared a DNA-mimic for the DNA frag­
ment from v-erb B oncogene, as described in Material 
and Methods. Primer templates were chosen so as to 
span a fragment containing part of an exon and part 
of the next exon from HMG-CoA lyase. The competitive 
PCR experiments for both mRNAs are shown in Fig. 7- 
Serial dilutions of the DNA-mimic were co-amplifieci 
with a constant amount of the HMG-CoA lyase cDNA 
fragment. Under competitive conditions, the absolute 
amount of DNA-mimic added to the reaction is equal to
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Fig. 5. PCR amplifications of the cDNAs of the proband, his parents, his brothers, and a human control. The oligonucleotides used were f3/ 
orf-r. The appearance of two bands corresponding to the two mRNAs (one the wild type and the other the deleted mRNA) is clearly seen in 
the parents and two brothers (U. C. and G. C.). The proband (E. G.) has only the deleted band. The third brother (K. C.) shows only the 
wild-type band in the two alleles, and is not a carrier of the disease,
Both
mRNAs
control patient
Inserted
mRNA
control patient
HMG-CoA
Lyase
ß-actin
Fig. 6. Top: Northern blot analysis of the HMG-CoA lyase mRNAs of a human control and the patient. The 
first two lanes (left) were hybridized with the PCR cDNA-amplified probe located far upstream from the locus 
of insertion and deletion (fragment comprised between oligonucleotides orf-f and r l) . The lanes of the right 
were hybridized with a PCR genomic DNA-amplified specific probe containing the 126 nucleotides correspond­
ing to the deletion and 72 nucleotides of the inserted intron. Bottom: The amounts of the RNA samples applied 
to the gel were compared by determining the mRNA levels of p-actin.
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Fig. 7. Titration of a DNA-mimic with a constant amount of two different types of the cDNA fragment. Three jxl (A) or 0.3 fil (C) of HI, 
cDNA from cultured fibroblasts was added to a PCR containing up to 625 serial dilutions of a DNA mimic, After 25 cycles of amplification, 
aliquots of about 30% of the volume were resolved on a %% ethidium bromide/agarose gel. Lanes 1-5 (A) correspond to amounts of 3.75 X 
10*, 7.5 X 102, 1.5 X 102, 30, and 6 attornoles of DNA mimic, respectively, whereas lanes 1-5 (C) correspond to amounts o f 22,5 X 10'*, 4.5 
X 104 , 9 X 103, 1.8 X 103, and 3.6 X 102 attornoles of DNA mimic, respectively. The positions of the 237 bp (A) of the HL mRNA with the 
insertion, 301 bp (C) of the HL mRNA with the deletion, and 596 bp of the DNA mimic products are indicated. (B) and (D). The relative 
amounts of HL mRNA and DNA mimic products were calculated after correcting for the difference in size between them. The log of the ratios 
of HL mRNA to DNA mimic products were plotted as a function of the initial amount of DNA mimic added to PCR.
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the amount of mRNA when the molar ratio of products 
becomes equal for target and DNA-mimic pairs. Molar 
equivalence occurs at approximately the point where 
equivalent amounts of radioactivity are incorporated 
into the mRNA and DNA-mimic. The relative amounts 
of target and DNA-mimic products were calculated after 
correcting for the difference in size between them. In 
the experiment shown in Fig. 7, molar equivalence was 
reached at 240 attornoles for the mRNA with the inser­
tion and 2,004 attornoles for the mRNA with the dele­
tion. Taking into consideration that the mass of the ali­
quot taken for the determination of the mRNA with the 
deletion was 1/10 of that of the mRNA with the inser­
tion, it became clear that the proportion of the two 
mRNAs is 1/83 that is, 1.20% of the total mRNA con­
tains the insertion.
DISCUSSION
The characterization of a first mutation causing IiL  
deficiency was recently reported (3). In the present 
study, which is the third performed at the molecular 
level in the HMG-CoA lyase gene, we report a novel 
point mutation of this gene in a Turkish patient with 
homozygous HMG-CoA lyase deficiency. By using a 
combination of methods (RT-PCR amplification, se­
quencing of the amplified cDNAs that were different 
from control, amplification and sequencing of an in- 
tron, and comparison of the results of the proband with 
those of his parents and brothers) we reached the con­
clusion that the proband was homozygous for a G ^ G  
transversion at position +1 of the intron downstream 
from the exon containing the catalytic site in the en­
coded protein.
There is no doubt that the GT dinucleotide is highly 
conserved at the 5' end of introns of most eukaryotic 
genes (24, 25). The first nucleotide of a normal intron 
is never C (24) and mutations of the strictly conserved 
G at this position prevent normal splicing (26). This 
guanine at position +1 is involved in binding U1 small 
ribonucleoprotein particles (U1 snRPNs) and this is the 
residue that undergoes cleavage in the spliceosome and 
lariat formation (27, 28). The G —» A mutation in the 
conserved splice donor site has been reported in several 
other human genetic diseases, and represents 64% of 
total G mutations reported in the splice donor site (29). 
G —» C transversions as reported in this article are less 
common. According to Cooper and Krawczak (30, 31), 
G —> C transversion represents 12% of all possibilities 
of change starting with GT and modifying the 5' nucleo­
tide.
In the present study we have demonstrated that the G 
—> C transversion at the 5' donor slice site of the intron
studied of the HMG-CoA lyase gene disrupts the normal 
splice site in that it causes: a) the use of an alternative 
normal splice site with the skipping of the exon up­
stream of the mutation; and b) the activation of one 
cryptic splice site, downstream (in the intron consid­
ered) from the normal splice site. The genomic organi­
zation of the HMG-CoA lyase gene has not yet been pub­
lished. However, after this study we can affirm that two 
introns are present at nucleotides 750 and 876 of the 
cDNA of HL. The intron located downstream of the 876 
bp of the cDNA (called intron X) is about 1.9 kb in 
length. The intron (X-l) is of unknown size. Our results 
also indicate that the use of an alternative normal splice 
site (exon skipping) was a pi~eferential mechanism of 
splicing as compared to the activation of a cryptic site, 
as the amount of the HMG-CoA lyase mRNA devoid of 
the exon deleted was much higher than that of the 
mRNA with the insertion. This is the opposite to what 
happens in most mutations at this G at the donor splice 
site. One explanation is that the cryptic splice site con­
tains a t rather than a g (usLially found in 84% propor­
tion) at the fifth position, and a I rather than an a (usu­
ally 64%) at the fourth position.
To obtain convincing evidence that the mutated pro­
tein lacks enzyme activity, it would be necessary to ex­
press the cDNA in a suitable cell culture such as E. coli 
or COS cells. However, this experiment is not required 
here because of the consequences of the mutation stud­
ied. The mRNA species that derives from the use of an 
alternative normal splice site produces a deleted pro­
tein that obviously leads to a nonfunctional enzyme. 
This is because the encoded protein derived from the 
deleted mRNA has lost the whole catalytic site, includ­
ing the catalytic cysteine-266, which, by itself, explains 
the occurrence of the disease. The consequences of the 
absence of enzymatic properties in the protein encoded 
by this mutated mRNA are exacerbated because this 
mRNA is practically the only one found.
The insertion of 78 nucleotides described herein in 
one of the two mRNAs of this proband constitutes a 
good example of an aberrant splicing produced by a 
single point mutation. The length of this insertion is 
due to a cryptic 5' splice site in nucleotides 79 to 83 of 
this intron, which is activated once the nearby func­
tional wild-type site is crippled by this mutation. The 
translation product of the mRNA derived from the acti­
vation of the ciyptic site in the intron contains 17 amino 
acid residues preceding a premature stop codon. Al­
though we have not studied the catalytic efficiency of 
the abnormally inserted and prematurely truncated 
protein, it is reasonable to assume that such great 
changes in the expected protein, that is, the inclusion 
of 17 aberrant amino acid residues, 22 amino acids from 
the catalytic cysteine, are enough to explain the null 
catalytic activity seen in the proband fibroblasts. An ad­
2430 Journal of Lipid Research Volume 37, 1996
ditional reason for the inability of the inserted protein 
to catalyze the enzyme reaction normally is that the sub­
stitution of the sequence in the carboxyl terminus by 
the nonsense amino acids eliminates the cysteine-323. 
The Cys-323 is involved in regulation and the inter-sub­
unit interaction in the homo dimer of the eukaryotic 
HMG-CoA lyase as judged by covalent modification and 
site-directed mutagenesis (18, 22). HMG-CoA lyase in 
Pseudomonas mevaloniiis present as a monomer, instead 
of a homodimer seen in eukaryotes (32). It is not un­
usual that the Cys-323 is lacking in HMG-CoA lyase from 
P. mevalonii as its function is not needed.
IiTespective of whether this truncated protein is func­
tional, in this individual, the expression of the mRNA 
with insertion is largely abolished. mRNA in Northern 
blot experiments was almost undetectable, and RT-PCR 
worked only in the cases in which the other mRNA was 
not primed, i.e., when we used primers located in the 
deleted area. By using the competitive PCR (the DNA- 
mimic PCR reaction) we determined that only 1.2% of 
the total mRNA contained the insertion. In other 
words, for the amplification of this mRNA we found a 
situation similar to the illegitimate transcription previ­
ously described (33). Alternatively, the mRNA tran­
scribed could be highly unstable.
The studies performed on the parents confirm the 
transversion G —> C at the nucleotide +1 observed in 
the proband. In addition, the occurrence of a double 
nucleotide at this position, the mutated C as in the 
proband and the wild type G as in the human control, 
shows that the parents were heterozygous for the same 
mutation. W
Note added in proof: According to the genomic organiza­
tion of HL reported recently by Wang et al. (Genomics. 1966, 
33: 99-104), we conclude that the exon deleted is exon 8.
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